Delinea Recognized as a Leader in the KuppingerCole Leadership Compass™ for Privileged Access Management (PAM) 2024
10.10.2024 09:00:00 CEST | Business Wire | Press release
Delinea’s Continued Innovation and Comprehensive Approach to Identity Security Highlighted in Leading Analyst Report
Delinea, a pioneering provider of solutions for securing identities through centralized authorization, today announced its recognition as a Leader in the KuppingerCole Leadership Compass for Privileged Access Management (PAM), 2024. This marks another significant milestone for Delinea as it continues to lead the industry in providing secure and scalable PAM solutions that empower organizations to safeguard their most critical identities and assets.
“We are honored to be recognized as a Leader in the 2024 KuppingerCole Leadership Compass for PAM,” said Art Gilliland, CEO of Delinea. “This achievement reflects our commitment to developing innovative solutions for the growing complexity of identity security. With our broad product portfolio and cloud-first approach, Delinea has established itself as a market leader known for ease of use. As human and machine identities increase, organizations require powerful yet simple-to-implement PAM solutions that reduce risk without sacrificing productivity. This recognition reinforces our leadership in addressing those needs.”
Delinea’s platform received acclaim for its robust capabilities throughout the entire PAM lifecycle, including discovery, governance, just-in-time access, and session monitoring. The report highlights Delinea’s market-leading, scalable, and user-friendly PAM solutions, which excel in cloud integration and Identity Threat Detection and Response.
Notably, Delinea was the only vendor to earn a “Strong Positive” rating for “Innovativeness,” with its solutions praised for ease of use, scalability, and strong cloud integration capabilities, featuring essential functions such as password vaulting, session management, and enforcement of least privilege access. making advanced security accessible and manageable for organizations of all sizes.
“We are pleased to recognize Delinea as a Leader in the 2024 KuppingerCole Leadership Compass for PAM,” said Paul Fisher, KuppingerCole Lead Analyst. “Delinea has demonstrated a strong commitment to innovation and user-friendly design, which are essential for organizations navigating the increasing complexity of identity security. Their focus on customer needs positions them favorably in the market, especially as demand for effective PAM solutions continues to rise.”
Delinea’s continued innovation and focus on customer needs have established it as a trusted partner in identity security. This recognition by KuppingerCole further cements Delinea’s position as a leader in the PAM market, helping enterprises worldwide to secure their most critical assets.
For more information on Delinea’s performance in the 2024 KuppingerCole Leadership Compass for PAM, visit https://delinea.com/resources/kuppingercole-leadership-compass-report.
About Delinea
Delinea is a pioneer in securing identities through centralized authorization, making organizations more secure by seamlessly governing their interactions across modern enterprise. It applies context and intelligence throughout the identity lifecycle, covering cloud and traditional infrastructure, data, and SaaS applications to eliminate identity-related threats. Delinea uniquely provides intelligent authorization for all identities, allowing precise user identification, appropriate access assignment, interaction monitoring, and swift response to irregularities. The Delinea Platform accelerates adoption and boosts productivity, deploying in weeks, not months, requiring just 10% of the resources compared to competitors. Discover more about Delinea on Delinea.com, LinkedIn, X, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010582144/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom